145 related articles for article (PubMed ID: 7915984)
1. Immunophenotyping specimens from HIV-infected persons: laboratory guidelines from the Centers for Disease Control and Prevention.
Nicholson JK
Cytometry; 1994 Mar; 18(1):55-9. PubMed ID: 7915984
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the impact of a CD4+ T-cell testing laboratory improvement program.
Rosner E; Siragusa M; Schalla W; Cross D; Cohn R; Hearn T
Arch Pathol Lab Med; 1998 Jun; 122(6):512-9. PubMed ID: 9625418
[TBL] [Abstract][Full Text] [Related]
3. 1994 revised guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus (HIV) infections. Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1994 Mar; 43(RR-3):1-21. PubMed ID: 7908403
[TBL] [Abstract][Full Text] [Related]
4. 1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1997 Jan; 46(RR-2):1-29. PubMed ID: 9011774
[TBL] [Abstract][Full Text] [Related]
5. Are there differences between laboratories that use or fail to use the CDC's guidelines to measure CD4+ and CD8+ T cells?
Ferbas J; Logar AJ; Harwell TS
Cytometry; 1995 Sep; 22(3):256-7. PubMed ID: 8556958
[No Abstract] [Full Text] [Related]
6. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression.
Gougeon ML; Lecoeur H; Dulioust A; Enouf MG; Crouvoiser M; Goujard C; Debord T; Montagnier L
J Immunol; 1996 May; 156(9):3509-20. PubMed ID: 8617980
[TBL] [Abstract][Full Text] [Related]
7. A multicenter evaluation of the PanLeucogating method and the use of generic monoclonal antibody reagents for CD4 enumeration in HIV-infected patients in Thailand.
Pattanapanyasat K; Shain H; Noulsri E; Lerdwana S; Thepthai C; Prasertsilpa V; Likanonsakul S; Yothipitak P; Nookhai S; Eksaengsri A
Cytometry B Clin Cytom; 2005 May; 65(1):29-36. PubMed ID: 15800883
[TBL] [Abstract][Full Text] [Related]
8. Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection.
MMWR Recomm Rep; 1992 May; 41(RR-8):1-17. PubMed ID: 1350319
[TBL] [Abstract][Full Text] [Related]
9. Quality control in immunophenotyping: U.S. efforts to establish common methodology and their impact. American Society for Histocompatibility and Immunogenetics.
Nicholson JK
Eur J Histochem; 1994; 38 Suppl 1():7-12. PubMed ID: 8547714
[TBL] [Abstract][Full Text] [Related]
10. Centers for Disease Control perspective on quality assurance for human immunodeficiency virus type 1 antibody testing. Model Performance Evaluation Program.
Valdiserri RO; Taylor RN; Hearn TL; Schalla WO; Muir HW
Arch Pathol Lab Med; 1990 Mar; 114(3):263-7. PubMed ID: 2154961
[TBL] [Abstract][Full Text] [Related]
11. CDC recommends new guidelines for HIV tracking. Centers for Disease Control and Prevention.
AIDS Alert; 1999 Feb; 14(2):17-8. PubMed ID: 11366172
[TBL] [Abstract][Full Text] [Related]
12. T-lymphocyte immunophenotyping blind proficiency testing: a model system for CD4+ T-cells.
Francis DP; Peddecord KM; Hofherr LK; Benenson AS; Taylor RN; Schalla WO
Clin Lab Sci; 1999; 12(5):278-89. PubMed ID: 10623327
[TBL] [Abstract][Full Text] [Related]
13. Centers for Disease Control and Prevention revised guidelines for human immunodeficiency virus (HIV) counseling, testing, and referral: targeting HIV specialists.
Powderly WG; Mayer KH
Clin Infect Dis; 2003 Sep; 37(6):813-9. PubMed ID: 12955643
[No Abstract] [Full Text] [Related]
14. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
Marchetti G; Gori A; Casabianca A; Magnani M; Franzetti F; Clerici M; Perno CF; Monforte Ad; Galli M; Meroni L
AIDS; 2006 Aug; 20(13):1727-36. PubMed ID: 16931937
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention.
Mandy FF; Nicholson JK; McDougal JS;
MMWR Recomm Rep; 2003 Jan; 52(RR-2):1-13. PubMed ID: 12583540
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of human immunodeficiency virus (HIV) type 1 load, CD4 T cell level, and clinical class as time-fixed and time-varying markers of disease progression in HIV-1-infected children.
Kalish LA; McIntosh K; Read JS; Diaz C; Landesman SH; Pitt J; Rich KC; Shearer WT; Davenny K; Lew JF
J Infect Dis; 1999 Nov; 180(5):1514-20. PubMed ID: 10515810
[TBL] [Abstract][Full Text] [Related]
18. Improving and assuring newborn screening laboratory quality worldwide: 30-year experience at the Centers for Disease Control and Prevention.
De Jesús VR; Mei JV; Bell CJ; Hannon WH
Semin Perinatol; 2010 Apr; 34(2):125-33. PubMed ID: 20207262
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
20. [Immunodeficiency and opportunistic processes in the absence of human immunodeficiency virus infection].
Soriano V; Castro A
Med Clin (Barc); 1993 Mar; 100(9):351-5. PubMed ID: 8095996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
